We have constructed a hybrid cDNA coding for a fusion protein between human interleukin 2 and a truncated heavy chain from human immunoglobulin M. The protein encoded by this cDNA contains the entire interleukin 2 sequence including its signal peptide, fused at its C terminus to domains 2 to 4 of the immunoglobulin heavy-chn constant region. Cells transfected with the hybrid cDNA secrete multimeric forms of the fusion protein, which bind specifically to cells bearing high-affinity interleukin 2 receptors. This binding leads either to T-cell proliferation or, if complement is added, to T-cell death. Multimeric forms of the fusion protein with a molecular mass above 500 kDa mediate complement-dependent lysis but trigger proliferation inefficiently when compared with forms with a low molecular mass (<500 kDa). In contrast, the latter efficiently mediate T-cell proliferation without inducing complement-dependent lysis. The high molecular mass fusion proteins could thus constitute valuable tools for specific immunosuppression in humans.
Organ transplants are being carried out with, increasing frequency and represent a powerful approach to the treatment of various organ end-stage diseases. One of the problems associated with this technique is graft rejection. Immunological events leading to rejection are initiated by the activation of genetically precommitted recipient T cells which recognize donor antigens. Reagents that would permit the selective destruction of these T lymphocytes, which represent <1% of the T-cell population (1, 2) , without interfering with the resting T-cell immune repertoire would thus find many uses. Activated, but not resting, T lymphocytes carry on their surface a high-affinity receptor for interleukin 2 (IL2) comprising at least two different chains, the a chain, or p55 (3) , and the P3 chain, or p75 (4) . Interaction of this receptor with IL2 is of crucial importance for T-lymphocyte proliferation. Various strategies for blocking graft rejection have been successfully developed which target this highaffinity receptor that is specific for the activated T-lymphocyte population (see refs. 5 and 6 for reviews).
Mouse monoclonal antibodies directed against IL2-binding epitopes of the p55 chain inhibit IL2 binding to the highaffinity receptor and block the IL2-driven growth ofactivated T lymphocytes (7) . These antibodies decrease alloimmune or delayed-type reaction in both animals (8) (9) (10) and humans (5, 6) . However, drawbacks of the antibodies are their relatively low affinity (as compared with IL2) for the receptor and their immunogenicity. Furthermore, binding of the IL2 receptor by the monoclonal antibodies does not lead to efficient complement-induced cytotoxicity. Hybrid human/mouse monoclonal antibodies against the IL2 receptor have been developed (11, 12) . In principle, these humanized antibodies should show reduced immunogenicity (production of fewer anti-isotypes), though anti-idiotypes may still be produced and act as blocking antibodies. Another approach is the use of IL2 molecules fused to bacterial toxins such as the diphtheria (13) or Pseudomonas (14) toxins. These molecules have a higher binding affinity for the IL2 receptor than the monoclonal antibodies (12) . Their internalization leads to toxin-induced cell death. They remain immunogenic, however (15) . This may be an important drawback with IL2-diphtheria toxin fusion proteins, as many people already possess anti-diphtheria antibodies.
The ideal reagent would be a fully humanized, poorly immunogenic structure with a high affinity for the IL2 receptor and good cytotoxic potential for activated T lymphocytes. Along these lines, an IL2-immunoglobulin fusion protein may have considerable advantages. Indeed, the utility of immunoglobulin (lg) fusion proteins has been demonstrated in studies developing reagents targeted to the AIDS virus (16, 17) . Also, a fusion protein between IL2 and the IgGI heavy-chain constant region (Cy) has been described with some complement-dependent cytotoxicity against IL2 receptor-positive cells (18) . However, a fusion protein between IL2 and the IgM heavy-chain constant region (C.M) would theoretically be more advantageous, resulting in more potent complement-mediated killing and in a higher avidity for the IL2 receptor due to multivalency. Furthermore, inhibition of the IL2-mediated signal after interaction of a multivalent fusion protein with the IL2 receptor is a real possibility (19) (20) (21) .
In this paper, we describe a human IL2-truncated IgM heavy-chain fusion protein. Multimeric forms of this fusion protein are toxic for activated T lymphocytes in the presence of complement but weakly trigger their proliferation in its absence. These molecules constitute a potential immunosuppressive drug for use in transplantation.
MATERIALS AND METHODS
Hybrid cDNA Construction. cDNA reverse-transcribed from Jurkat cell RNA was used as a template for the polymerase chain reaction with oligonucleotide primers derived from the human IL2 cDNA sequence: primer 1, 5'-CGTCGACTCCTGCCACAATGTACAGG-3'; primer 2, 5'-CGGATCCAGTCAGTGTTGAGATGATGC-3'. Primer 'lTo whom reprint requests should be addressed.
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Proc. Natl. Acad. Sci. USA 89 (1992) in place of the IL2 stop codon. Use of these primers generated a 0.48-kilobase-pair (kb) Sal I-BamHI fragment.
A partial C, cDNA clone (21) was used as a template for the polymerase chain reaction with the following primers (22) chain polyclonal antibody or with 2.5 &g of rabbit anti-human IL2 polyclonal antibody (Genzyme). After addition of excess protein A-Sepharose (Bio-Rad), samples were incubated overnight at 4°C with gentle agitation. After extensive washings, bound proteins were subjected to SDS/PAGE analysis. Eectrophoresis. SDS/PAGE was carried out (24) in 4.5-16% and 3-7% polyacrylamide gradient slab gels. Gels were then subjected to autoradiography. Cation-Exchange and Gel Filtration Chromatography. Two liters of supernatant from transfected CHO cells was diluted 2-fold in 20 mM phosphate buffer (pH 7) (buffer A), and the pH was adjusted to 7 with HCL. The diluted supernatant was passed at 4°C and at 3 ml/min through a cation-exchange column (Hiload S-HP 16/10 from Pharmacia France) previously equilibrated in buffer A. The column was rinsed with buffer A and two elution steps were carried out with buffer A containing first 0.5 M and then 1 M NaCl. The fraction eluted at 0.5 M NaCl was then loaded at 4°C onto a Sephacryl S-300 gel filtration column (Hiload 26/60 from Pharmacia France) previously equilibrated with buffer A containing 1.5 M NaCl. Fractions were collected every 4 min at 0.5 nl/min.
Cell Lines. CTLL-2 is an IL2-dependent murine T-cell line; 4AS is a human alloreactive T-cell clone (25) ; the B-lymphoblastoid cell line (BLCL) is a human B-cell line obtained by transformation with Epstein-Barr virus; DA-la is an IL3-dependent murine cell line (26); K562 is a human erythromyeloblastoid cell line; JAR is a human neuroblastoma line (ATCC; HTB 144); and Jurkat is a human leukemic T-cell line. (27) .
Estimation of IL2-Mu Binding Affinity. The affinity of purified high molecular mass (>500-kDa) IL2-Mu species for the IL2 receptor on CTLL-2 cells was estimated with flow cytometry by titrating the mean fluorescence obtained with 0-20 nM IL2-Mu and a biotinylated anti-human IgM antiserum (Kallested).
RESULTS
Hybrid cDNA Construction. We constructed a hybrid cDNA (see Materials and Methods and Fig. 1 ) coding for a secreted fusion protein, IL2-Mu, in which the IL2 and C, sequences are joined together by a two amino acid linker, Gly-Ser. The fusion protein should be able to use the IL2 sequence to bind to the IL2 receptor and use the C, sequence to bind complement. In addition, because the fusion protein contains the cysteine residues implicated in multimerization of IgM heavy chains (Fig. 1) , it should itself form multimers.
A variant form of the hybrid cDNA was also produced by reversing the orientation of a BstEII fragment (see IL2-Um cDNA, Fig. 1 Growth. Fusion proteins were tested for their ability to promote the growth of the IL2-dependent murine T-cell line CTLL-2 or lectinactivated human T lymphocytes. Supernatant from COS-1 cells transfected with pIL2-Mu or pIL2-Um, unlike that from cells transfected with the "empty" expression vector pKCSRa, specifically elicited proliferation of both murine (Fig. 2) complement were used (Fig. 4) . The phenomenon was specific, as IL2 receptor-negative cell lines (such as K562 or BLCL) were not killed under the same assay conditions.
Purificao and Anyis of the Varos 112-Mu Molecular Forms. Supernatant from pIL2-Mu6-transfected CHO cells was subjected to immunoprecipitation, and bound proteins were eluted and analyzed by SDS/PAGE in 4.5-16% (Fig. 5 ) and 3-7% (data not shown) polyacrylamide gradient slab gels under reducing and nonreducing conditions. Identical immunoprecipitation patterns were obtained with either anti-IL2 or anti-gM antibodies (Fig. 5) , demonstrating that the recombinant material secreted by transfected CHO cells comprised both the IL2 and the it-chain moieties. Under nonreducing conditions, various molecular forms could be distinguished ranging from 68 to 650 kDa (Fig. 6) , whereas under reducing conditions, a single band was observed with the expected molecular mass of the monomeric form (68 kDa). We deduced that IL2-Mu was obtained as a mixture of forms raning from monomers to decamers. A two-step chromatographic protocol allowed purification of IL2-Mu from crude CHO supernatant. A cation exchanger bound all the IL2-Mu while eliminating 95% of the total protein input in the flow-through (data not shown). After elution with 0.5 M NaCl, the EL2-Mu fraction obtained was enriched 60-fold compared with the crude supernatant. Further purification was obtained by gel filtration. Total IL2-Mu recovery as tested by ELISA was 82%. Each fraction was tested in an ELISA to quantitate the amount of IL-2Mu, and in both proliferation and cytotoxicity assays to compare the respective functional activity of the various IL2-Mu forms. Two main IL2-Mu-containing fractions could be distinguished, one of high molecular mass (>500 kDa) and one of low molecular mass (<500 kDa). The former fraction was found to contain most of the cytotoxic activity and showed a low proliferative activity. Conversely, the latter fraction was not cytotoxic but contained most ofthe proliferative activity. For example, in the experiment shown in Fig. 6 , the IC50 cytotoxicity/IC50 proliferation ratio was 256/7.9 for fraction number 2 and 0/40 for fraction number 36. eventually reaching a plateau. The apparent affinity of the high molecular mass IL2-Mu fraction (>500 kDa) could therefore be derived by fitting the data to a simple hyperbolic saturation function. The apparent dissociation constant (Kd) derived from five independent experiments was 450 + 130 pM.
DISCUSSION
Our results allow some observations to be made about the structural behavior of IL2 fusion proteins. First, it is clear that IL2 can be fused to other sequences either via its C terminus (our results) or via its N terminus [IL2-diphtheria toxins (13) ] without losing its capacity to bind to the IL2 receptor. Second, the ability ofbound IL2-Mu to induce lysis of IL2 receptor-positive cells in the presence of complement demonstrates that its Clq binding site is exposed under these circumstances. In a natural IgM, an IgM-ligand interaction triggers a conformational change required to expose the Clq binding site. It remains to be determined whether this site is always exposed or whether it becomes exposed only after binding of IL2-Mu to its receptor. Finally, the truncated CA chain induces multimerization of IL2-Mu. Gel filtration analysis demonstrated that although the fusion protein was secreted as a mixture of multimers of different molecular mass, only the high molecular mass forms possessed cytotoxic potential.
The low mitotic induction by large polymeric IL2-Mu forms (>500 kDa) is likely to be related to modifications in IL2-receptor internalization (28) . Indeed, this is reminiscent of the inhibitory effect on IL2-driven growth of activated cells by IgM monoclonal antibodies directed against an IL2-noncompeting epitope on the p55 chain of the IL2 receptor, whereas corresponding monovalent fragments from the same IgM were not inhibitory (19) . This has been confirmed recently in a human system (20) . Whether this inhibition of IL2-driven proliferation by high molecular mass forms of IL2-Mu would play a role in vivo, where complement-mediated cytotoxicity, opsonization, or antibodydependent cell-mediated cytotoxicity can operate, remains unknown.
Similarly, only in vivo experiments will tell whether the large multimeric forms of IL2-Mu have access to the site of the immune response. However, it is noteworthy that IL2 receptor-positive cells are not restricted to graft tissues but migrate in the blood. It has also been reported that cytotoxic IgM monoclonal antibodies have a high efficiency in vivo (29) .
The affinity of large forms of IL2-Mu (>500 kDa) for the IL2 receptor has been repeatedly evaluated by flow cyto- Besides its ability to effect complement-mediated killing, a major potential advantage of the presented fusion molecule lies in its human nature. Indeed, so far, all bioreagents used in immunosuppressive treatments elicit a rapid immune response in vivo. This is well known for unmodified monoclonal antibodies against the IL2 receptor (5) or CD3 determinants (30) . Chimeric or complementary determinant-region recombinant molecules derived from them (11) will probably decrease the incidence of host immunization but cannot in theory avoid production of blocking anti-idiotypic antibodies. IL2-toxin fusion proteins cannot trigger IL2-blocking antibodies, but the bacterial toxin component of these fusion proteins may elicit antibodies (15) . In contrast, the fusion protein we describe contains only human sequences and will probably not elicit antibody production when administered to humans, which would allow long-term treatment with this reagent, although we cannot rule out the possibility that conformational antibodies can be elicited against this fusion protein.
The protein we describe may thus prove to be particularly advantageous in the treatment of allograft recipients and of patients with autoimmune diseases or bearing tumors expressing the IL2 receptor. In addition, the strategy we describe here can clearly be adapted for the construction of other fusion proteins containing different ligands linked to the IgM heavy chain.
